NCT05561374 2024-11-29Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade GliomaOblato, Inc.Phase 1 Active not recruiting16 enrolled
NCT03649464 2022-10-07Investigation of Oral OKN-007 in Recurrent High-grade Glioma ParticipantsOblato, Inc.Phase 1/2 Withdrawn